NYSE: TFX · Medical Instruments & Supplies
Teleflex (TFX) fair value and price range
As of 31 Oct 2026, Faircurve's model values Teleflex (TFX) at $142.86 a share. The stock last closed at $152.15, which puts the model's fair value 6.1% below the price. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
Revalued . Price is the close of 5 Nov 2026. Teleflex Incorporated.
The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 31 Oct 2026 moved the fair value from $139.53 to $142.86 (+2.4%). The stock's own trading multiple rose with its price, and the fair value follows it in part: most of the move.
What the model makes of itThe price of $152.15 is 6.1% above it. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
What's nextNext report on 25 Feb 2027. Options prices imply a move of about 10% either way over the next month. The next weekly run is on Saturday 7 Nov 2026.
What price range does the model give TFX?
The calibrated range for TFX over 63 trading days is $137.77 to $171.88. It sits around the last close, and its width comes from the volatility that TFX's own options imply (33% a year), calibrated weekly against realised prices (n = 6,661 past valuations, refreshed 31 Oct 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $77.09 to $232.96. In 51% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 31 Oct 2026
Teleflex Incorporated is a global medical technology company. It designs, develops, manufactures and distributes single-use medical devices.
Faircurve's model put the fair value at $142.86 a share on 31 Oct 2026, the midpoint of 2,000 simulations. The previous run, on 24 Oct 2026, gave $139.53, so the fair value moved +2.4%. In the model's own words, "The stock's own trading multiple rose with its price, and the fair value follows it in part: most of the move." The calibrated range over 63 trading days is $130.53 to $177.60. Ranges built this way held the price 60% of the time at this horizon, based on 6,661 past valuations refreshed on 31 Oct 2026. The model grades the evidence behind this valuation as low, so no verdict is shown.
The model's overall quality score for Teleflex is 59 out of 100, a composite of six quality factors scored against comparable companies. Three factors stand out. Earnings quality scores 100. Capital discipline scores 98, with net buybacks at 4.2% of market value against a peer median of 0.0%. Profitability scores 29, with ROIC at 1.5% against a peer median of -0.3%. The model compares Teleflex with Merit Medical Systems, ICU Medical, AptarGroup, Repligen, The Cooper Companies and Baxter International. Envista Holdings Corp and Avantor are also compared, but have no verdict on this date.
Written from the figures on this page for the 31 Oct 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does TFX report earnings, and how has the stock reacted?
Teleflex's next earnings report is scheduled for 25 Feb 2027. Companies can move their dates.
Options prices on 5 Nov 2026 imply a move of about 6.1% in either direction through the nearest expiry, about 14 days out. That is the size the market is pricing, not a direction. TFX's 30 day implied volatility works out to about 9.6% over one month.
On 4 Nov 2026 TFX moved 7.1% in one session, against the 2.9% a day that options had priced: 2.5 times the implied size, around an earnings report.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across TFX's last 8 reports, ignoring direction, was 8.5%.
What the options market has priced for a month's move in TFX
How does TFX score on business quality?
Teleflex's overall quality score is 59 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 29 | 1.5%ROIC | -0.3% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 100 | ||
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 45 | -34.6%Revenue growth, trailing | 9.1% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 98 | 4.2%Net buybacks / market value | 0.0% |
| Balance sheetNet debt to EBITDA and interest coverage. | 70 | -16.23xNet debt / EBITDA | 9.32x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 45 | 4.8 ptsEBITDA margin downside volatility, 5y | 3.7 pts |
How does TFX compare with similar companies?
The companies in medical instruments & supplies closest to Teleflex in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| MMSI Merit Medical Systems, Inc. | $89.62 | $81.34 | -9.2% | Fairly valued |
| ICUI ICU Medical, Inc. | $167.65 | $193.63 | +15.5% | Undervalued |
| ATR AptarGroup, Inc. | $144.04 | $132.22 | -8.2% | Fairly valued |
| NVST Envista Holdings Corp | $24.96 | $27.44 | +9.9% | Low evidence grade |
| AVTR Avantor, Inc. | $15.14 | $18.19 | +20.1% | Low evidence grade |
| RGEN Repligen Corporation | $168.48 | $142.95 | -15.2% | Overvalued |
| COO The Cooper Companies, Inc. | $63.51 | $68.01 | +7.1% | Fairly valued |
| BAX Baxter International Inc. | $25.65 | $23.62 | -7.9% | Fairly valued |
What the comparable companies' multiples alone would give for TFX, the peer-implied price, is $151.13 a share on this run. The fair value weighs that against the company's own multiple.
All medical instruments & supplies stocks ranked by gap to fair value
Teleflex at a glance
Teleflex Incorporated is a global medical technology company dedicated to designing, developing, manufacturing, and distributing single-use medical devices.
- Market value
- $5.9B
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Revenue expected, next twelve months
- $2.4B
- Consensus revenue growth, next fiscal year
- +13.8%
- Analysts with estimates
- 6
- Beta to the US market
- 0.52
- First valued by Faircurve
- 11 Jul 2026
How the fair value is worked out: the model prices Teleflex on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 24 Oct 2026 the model's fair value for TFX was $139.53. As of 31 Oct 2026 it is $142.86, a change of +2.4%. The stock's own trading multiple rose with its price, and the fair value follows it in part: most of the move. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Teleflex's valuation
Is Teleflex stock undervalued or overvalued?
Faircurve's model puts TFX's fair value at $142.86 a share against a last close of $152.15, as of 31 Oct 2026. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
What is TFX's fair value?
$142.86 a share as of 31 Oct 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $77.09 to $232.96.
What price range does the model give TFX?
$137.77 to $171.88 over 63 trading days. Ranges built this way held the price 60% of the time across 6,661 past valuations, refreshed 31 Oct 2026.
When does Teleflex report earnings next?
The next report is scheduled for 25 Feb 2027. Companies can move their dates.
How much has TFX moved on past earnings reports?
Across its last 8 reports the median two session move was 8.5%, ignoring direction. The largest was -25.3% around the report of 27 Feb 2025.
How confident is the model in this valuation?
The model's evidence grade for TFX is low. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on TFX
The model holds no idea open on TFX today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on TFX with their outcomes. A free account is enough.